Eli Lilly and Company (NYSE:LLY) Shares Down 1.3% – What’s Next?

Eli Lilly and Company (NYSE:LLY)’s stock price was down 1.3% during trading on Friday . The company traded as low as $899.29 and last traded at $905.3030. Approximately 4,721,948 shares were traded during mid-day trading, an increase of 46% from the average daily volume of 3,226,227 shares. The stock had previously closed at $917.50.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: TRANSCEND‑T2D‑1 Phase 3 topline: Retatrutide produced large A1C reductions and ~16.8% average weight loss at 40 weeks—data that support a potential new class-leading product and long-term growth for LLY. Retatrutide PR
• Positive Sentiment: High‑profile bullish commentary: Jim Cramer publicly said “buy” on Lilly, and several investment pieces reiterate Lilly as a top obesity bet—these endorsements can support demand and attract retail/institutional interest. Cramer Buy Call
• Neutral Sentiment: Analysts and research houses see retatrutide as a material growth driver but note mixed tolerability vs. rivals; RBC and others balance the strong efficacy with safety/tolerability questions. This creates a watchful, data‑driven trading environment rather than a clear consensus. RBC on Retatrutide
• Neutral Sentiment: Pipeline breadth updates (digital sleep tech for early Alzheimer’s, new diabetes candidate completion in Japan, master IBD trial, mirikizumab delivery study) reinforce long‑term optionality but are incremental near‑term drivers. TipRanks Pipeline Updates
• Negative Sentiment: Analyst downgrades: HSBC and other firms have trimmed ratings, prompting selling pressure and headline volatility. Analyst moves are directly contributing to today’s weakness. HSBC Downgrade
• Negative Sentiment: Safety note: new trial data flagged an unusual skin reaction for retatrutide (while overall tolerability is broadly comparable to rivals), which could slow clinician adoption or require label/monitoring considerations. Skin Reaction Report
• Negative Sentiment: Competitive pressure: Novo Nordisk’s FDA clearance of a higher‑dose Wegovy adds near‑term pricing and share‑gain risk in obesity market—intensifies the competitive landscape for LLY’s GLP‑1/combination programs. Wegovy Higher Dose Approval

Analysts Set New Price Targets

A number of analysts recently weighed in on LLY shares. Wolfe Research lifted their price target on Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the company an “outperform” rating in a research note on Wednesday, December 3rd. Leerink Partners raised their target price on Eli Lilly and Company from $1,234.00 to $1,296.00 and gave the company an “outperform” rating in a report on Thursday, February 5th. Argus boosted their target price on shares of Eli Lilly and Company from $930.00 to $1,200.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. Guggenheim increased their price target on shares of Eli Lilly and Company from $1,161.00 to $1,168.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $1,221.44.

Eli Lilly and Company Stock Performance

The company has a market capitalization of $855.35 billion, a price-to-earnings ratio of 39.45, a PEG ratio of 1.07 and a beta of 0.40. The stock has a fifty day moving average price of $1,026.34 and a two-hundred day moving average price of $954.98. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. The company had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The firm’s quarterly revenue was up 42.6% on a year-over-year basis. During the same period in the prior year, the firm earned $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Institutional Investors Weigh In On Eli Lilly and Company

Several hedge funds have recently modified their holdings of LLY. Brighton Jones LLC boosted its holdings in Eli Lilly and Company by 22.0% in the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after acquiring an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC raised its holdings in shares of Eli Lilly and Company by 2.8% in the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after purchasing an additional 40 shares during the period. Schnieders Capital Management LLC. lifted its stake in shares of Eli Lilly and Company by 16.7% in the 2nd quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock valued at $6,231,000 after purchasing an additional 1,141 shares in the last quarter. Quilter Plc grew its holdings in shares of Eli Lilly and Company by 18.4% during the 2nd quarter. Quilter Plc now owns 18,268 shares of the company’s stock worth $14,240,000 after purchasing an additional 2,835 shares during the period. Finally, PKS Advisory Services LLC grew its holdings in shares of Eli Lilly and Company by 53.8% during the 2nd quarter. PKS Advisory Services LLC now owns 932 shares of the company’s stock worth $726,000 after purchasing an additional 326 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.